9th Mar 2015 08:40
LONDON (Alliance News) - Proteome Sciences PLC said Monday its biomarker services division has "got off to a good start in 2015", signing five biomarker contracts.
The biotechnology firm said it has seen an increase in demand for its SysQuant assay tool, its Tandem Mass Tag calibrator, and TMT Ms3 mass spectrometry workflow product from pharmaceutical customers. This has bolstered its growing pipeline of firm orders and quotations that Proteome Sciences expects to close in the first or second quarter of 2015, it said.
Additionally, the company was issued a US patent covering methods of screening inhibitors of tau phosphorylation by casein kinase 1, which it said expands its intellectual property in Alzheimer's disease. Tau proteins can cause dementias of the nervous system like Alzheimer's disease when they become defective, and can no longer perform their function of stabilising microtubules property.
Its marketing dossier detailing the out-license of its two casein kinase 1 compounds against tau aggregation in Alzheimer's disease has received positive feedback, Proteome said.
Shares in Proteome are trading up 4.4% at 22.45 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Proteome